Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.16 HKD | -0.81% | +6.39% | -8.47% |
Jun. 03 | Simcere Pharmaceutical’s Cancer Drug Shows Positive Results | MT |
Jun. 03 | Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 49% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.47% | 2.03B | - | ||
+18.09% | 41.07B | B- | ||
+24.16% | 22.65B | B+ | ||
+15.71% | 15.02B | - | ||
+20.11% | 14.14B | B+ | ||
+52.15% | 12.09B | B | ||
-10.97% | 6.91B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+15.28% | 5.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2096 Stock
- Ratings Simcere Pharmaceutical Group Limited